Business & Finance

Novo Nordisk A/S completes investment in biopharma company

Published in Hepatitis Weekly, September 27th, 2004

Transition Therapeutics Inc. (Transition) (TSX: TTH) announced the closing of a previously announced issuance of 5,000,000 common shares to Novo Nordisk A/S (Novo Nordisk) at a price of $1.20 per share for cash proceeds of $6 million.

The private placement is part of a licensing agreement between Transition and Novo Nordisk. The shares issued to Novo Nordisk are subject to a 4-month hold period.

Proceeds from the financing will be used by Transition for ongoing research and development and for general corporate purposes.

Transition is a product-focused biopharmaceutical company, developing novel approaches and therapeutics for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry